Valley Grande Manor gave olanzapine to a male resident with Alzheimer's disease and vascular dementia, according to a federal inspection completed January 30. The facility's own nurses and pharmacist told inspectors the medication posed deadly risks for patients with his conditions.
The resident had severely impaired cognition, scoring just 3 out of 15 on a standardized cognitive assessment. His medical record showed diagnoses of Alzheimer's disease and vascular dementia, conditions that progressively destroy memory and thinking skills.
Despite these diagnoses, physicians ordered olanzapine 10 mg twice daily for the resident, listing "Alzheimer's disease, unspecified" as the indication. The order carried no end date.
The facility's pharmacist was direct about the danger during a phone interview with inspectors. Alzheimer's disease was not an appropriate diagnosis for an antipsychotic medication, the pharmacist said. Antipsychotics for residents with Alzheimer's disease could cause death.
The assistant director of nursing echoed this warning. The negative outcome for ordering antipsychotic medication for Alzheimer's disease could cause death, she told inspectors. That was why antipsychotics were not recommended for residents with Alzheimer's or dementia.
Yet the medication continued. Records showed the resident received olanzapine from January 6 through January 5, administered according to the physician's order.
When confronted by inspectors, the director of nursing defended the decision. She stated the indication of Alzheimer's disease was allowed because the resident came with that order from the hospital.
The explanation contradicted the facility's own policy on antipsychotic use. Valley Grande Manor's written guidelines, revised in December 2016, specified that antipsychotic medications could be considered for dementia residents only after medical, physical, functional, psychological, emotional, psychiatric, social and environmental causes of behavioral symptoms had been identified and addressed.
No evidence in the inspection report suggested this comprehensive evaluation occurred.
The resident's care plan acknowledged he used antipsychotic medications related to Alzheimer's disease. Staff were instructed to monitor for side effects and effectiveness every shift, and to document and report any adverse reactions to the antipsychotic medications.
Orders for side effect monitoring and behavior monitoring began December 31, 2025, the day before the olanzapine prescription started. Both monitoring orders ran every shift with no specified end date.
The case illustrates a broader problem in nursing home care. Federal regulations prohibit facilities from using unnecessary psychotropic medications or medications that restrain a resident's ability to function. The rules aim to protect vulnerable residents from chemical restraints disguised as medical treatment.
Olanzapine belongs to a class of drugs called atypical antipsychotics. Originally developed to treat schizophrenia and bipolar disorder, these medications carry serious risks for elderly patients, particularly those with dementia.
The resident's MDS assessment, completed January 6, classified him as being on a high-risk drug due to the antipsychotic. The assessment confirmed his severely impaired cognitive state, with a BIMS score indicating significant mental decline.
Vascular dementia, one of the resident's diagnoses, results from reduced blood flow to the brain that damages or kills brain cells. Combined with Alzheimer's disease, his condition represented a progressive, irreversible deterioration of cognitive function.
The facility's own staff understood these risks. During interviews, both the pharmacist and assistant director of nursing specifically mentioned death as a potential outcome of inappropriate antipsychotic use in dementia patients.
The director of nursing's justification that the hospital had initiated the order did not address whether the facility had an obligation to reassess the medication's appropriateness upon admission. Federal regulations require nursing homes to ensure residents receive only necessary medications, regardless of their source.
The inspection found the facility failed to have an adequate indication for olanzapine use. Inspectors determined this failure could put residents at risk of receiving unnecessary psychotropic medications.
Valley Grande Manor's policy required identifying and addressing multiple potential causes of behavioral symptoms before considering antipsychotic treatment. The policy suggested a systematic approach to understanding why residents might exhibit challenging behaviors.
No documentation in the inspection report indicated such an evaluation took place for this resident. The physician's order simply listed Alzheimer's disease as the indication, despite staff knowledge that this diagnosis alone did not justify antipsychotic treatment.
The case raises questions about medication oversight at the facility. While staff monitored for side effects and behavioral changes, they continued administering a medication their own experts said could prove fatal for the resident's condition.
Federal inspectors classified the violation as causing minimal harm or potential for actual harm, affecting few residents. However, the acknowledgment by facility staff that the medication could cause death suggests the potential consequences were severe.
The resident's admission record dated January 29, 2026, showed he had recently entered the facility. Within days, inspectors were documenting concerns about his medication regimen.
The inspection occurred following a complaint, though the report does not specify the nature of the complaint that triggered the federal review.
Valley Grande Manor's handling of this case demonstrates how nursing homes sometimes continue inappropriate treatments initiated elsewhere, despite having both the knowledge and obligation to reassess their necessity. The facility's own staff recognized the deadly risks, yet the medication continued without proper justification.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Valley Grande Manor from 2026-01-30 including all violations, facility responses, and corrective action plans.